Greg Durm

Terrific dinner with colleagues and friends before the @IndianaUniv Lung Cancer Symposium! Thanks to Dr Durm @gdurm and IU for the invitation and being such wonderful hosts! Looking forward to a day of learning tomorrow! #lcsm

New #JITC article: Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081 bit.ly/44WS2xZ @gdurm @HirvaMamdani @SalmaJabbour1 @AparGanti @ShadiaJalal @DrJNaidoo @maryjofidlerMD @LealTiciana @DrLFeldman1

Randomized Ph II trial: 6m consolidation nivo (N) or ipi/nivo (I/N) in stage III unresectable NSCLC @jitcancer - 18m-PFS 65.5% N, 66.3% I/N - mOS 32m, NR - g3+ TRAE 18.5% v 29.4% Congrats @gdurm @BigTenCRC 🏆, pleased to contribute as @HopkinsThoracic PI jitc.bmj.com/content/13/7/e…

Dr. Anita Turk discusses Advances in Biomarker Based Management in Mets Colorectal Ca @IUCancerCenter @IUHemOnc @anita_turk

Dr. Rebecca Hassoun presenting outcomes with salvage high dose chemo and transplant in relapsed GCT based on radiographic vs tumor marker progression @rebeccahassoun @IUCancerCenter @IUHemOnc

Indiana University reception at #ASCO2025 . Proud to work with a fantastic group of past, present, and future colleagues @IUCancerCenter @IUHemOnc @IU_UroOnc @rabonour1 @ChrisSweens1 @Noah_Onc @ASCOPres @ahmadalhader @gdurm @hannawants2ELCN @JenSchwartzIUSM

Why do people get ALK+ lung cancer? Why do some respond well to treatments and others less so? How can we better treat this disease? Lung cancer research is not just about answering these key questions, but about hope. It's why Dr @AngelQinMD believes #MoreResearchMoreLife.

ctDNA+ in consolidation IO trial (BTCRC 16-081) associates with outcomes in stage III unresectable NSCLC @JTOonline: - Tumor-informed ctDNA MRD analysis post CRT, C2D1 IO, & post 6m of IO - ctDNA+ assoc with ⬇️PFS at all timepts @OncoAlert @gdurm #LCSM jto.org/article/S1556-…

When you’re given a platform, you use it. Women: You can be great mothers and have successful careers. These are not mutually exclusive. Huge thanks to the UCSD Medical School graduating class for inviting me to speak this year! #womeninmedicine

LAURA Trial receives a well deserved huge applause by the audience. Huge benefit in PFS (39 vs 5.6 mo, HR < 0.2. OS still immature and 81% crossover. STAGE III EGFR+ NSCLC INCURABLE? BRAIN RMN BUT NO PET-CT required at baseline. #ASCO24 @LeciaSequist

Having seen LAURA, Dr Jayakrishnan presents retrospective ALK+ unresectsble st3 outcomes by consolidation Rx ost. Chemo-RT. ALK TKI rwPFS huge va no consolidation. Translates to OS benefit. Reinforces @LeciaSequist message that TKI consolidation important for AGA NSCLC #ASCO24

#ADRIATIC - new standard of care in #SCLC, where we have not seen an advance in >2 decades. Truly historic data with use of immunotherapy consolidation #LungPlenary @DavidRSpigel @LaurenByersMD @ASCO #ASCO24 @OncoAlert

EVOKE-01 from #ASCO24 @JCO_ASCO. Phase III study of the Trop2 ADC sacituzumab govitecan vs docetaxel in NSCLC post chemo/IO. Did not meet OS endpoint (11.1 vs 9.8m, HR 0.84) but numeric improvement in squamous & non-sq. If nonresponsive to IO, OS HR 0.75 ascopubs.org/doi/10.1200/JC…

CROWN results from #ASCO24 @JCO_ASCO: phase III 1L lorlatinib vs crizotinib in #ALK NSCLC. With 5y median f/u, median PFS not reached. 5y PFS rate 60% with lorlatinib (8% with crizotinib), median time to intracranial progression NR vs 16.4m (HR 0.06). ascopubs.org/doi/10.1200/JC…

KRYSTAL-12: Adagrasib vs Doce in KRAS G12C ✅ ⬆️ PFS HR=0.58 ✅ ⬆️ ORR 32 v 9% ✅ ⬆️ icRR 24 v 11% ❗️29% crossover ❗️⬆️ dose reduction, interruption + SAE 🤔 PFS benefit still modest 🤔 OS should be primary EP 🤔 CNS activity important 🤔 Toxicity significant #ASCO24 #LCSM

POP QUIZ: Is this a waterfall plot for a new lung cancer TKI? Nope…SEZ6 ADC for Relapsed Small Cell Lung Cancer (and other NECs). #SCLC #LCSM. @MDAndersonNews Thank you to the study team and all of our investigators, patients and families. @ASCO #ASCO24

Olomorasib (G12Ci) + Pembro, Ph1b ✅ ORR = 77% (1L), 40% (2L+) ✅ Irrespective of PD-L1 🔺 Gr3 AE = diarrhoea (13%), liver (6–8%), pruritis ❓Liver tox shortlived 🤔 Encouraging activity 🤔 Ph3 data needed 🤔 Severe tox in other immuno combos not seen here 👍 #ASCO24 #LCSM

Press release: phase III ADRIATIC study of durvalumab after chemoradiation for limited stage #SCLC improves both PFS and OS. Follows the PACIFIC approach, randomizing after definitive chemoradiation. Await data on durva + tremelimumab arm. #LCSM astrazeneca.com/media-centre/p…

Press release: phase III LAURA trial meets primary endpoint. Stage III #EGFR NSCLC post chemoradiation, indefinite osimertinib superior to placebo. No surprise - eager to see magnitude of benefit, patterns of relapse, OS trends, and crossover rate… astrazeneca.com/media-centre/p…

FDA approves repotrectinib (Augtyro) for #ROS1 NSCLC based on the phase I/II TRIDENT trial with 1L RR was 79% with mDOR 34.1m and after ROS1 TKI therapy, RR 38% with mDOR 14.8m. Also has activity at #NTRK (which mediates some toxicity). reuters.com/business/healt…